CHI3L1 and primary progressive multiple sclerosis: Lamancova et al. [94] evaluated serum levels of sNfL, CXCL13 and CHI3L1, among other molecular biomarkers, and noted that they were significantly higher in PPMS and SPMS patients compared with RRMS.